De novo design of peptidic positive allosteric modulators targeting TRPV1 with analgesic effects
ID:32
View Protection:ATTENDEE
Updated Time:2021-08-05 16:48:41
Hits:1086
Oral Presentation
Abstract
Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel is a nociceptor critically involved in pain sensation. Direct blockade of TRPV1 exhibits significant analgesic effects but also incurs severe side-effects such as hyperthermia, causing failures of TRPV1 inhibitors in clinical trials. In order to selectively target TRPV1 channels that are actively involved in pain-sensing, we de novo designed peptidic positive allosteric modulators (PAMs) based on the high-resolution structure of the TRPV1 intracellular ankyrin-repeat like domain. We optimized the hot-spot centric approach (OHCA) for protein design; its usage in Rosetta increased the success rate in protein binder design. We demonstrated experimentally, with a combination of FRET imaging, surface plasmon resonance and patch-clamp recording, that the designed PAMs bind to TRPV1 with nanomolar affinity and allosterically enhance its response to ligand activation as we designed. We further demonstrated that the designed PAM exhibits long-lasting in vivo analgesic effects in rats without changing their body temperature, suggesting that they have potentials for developing into novel analgesics.
Comment submit